Exelixis (EXEL) Cash from Financing Activities (2010 - 2026)
Exelixis (EXEL) recorded quarterly Cash from Financing Activities of -$457.1 million in Q2 2026, down 79.56% quarter-over-quarter from -$254.6 million in Q1 2026, and down 55.05% on a YoY basis from -$1.0 billion in Q2 2025.
Exelixis (EXEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Exelixis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$457.1 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 55.05% year-over-year to -$457.1 million; the TTM figure through Apr 2026 stood at -$1.1 billion (down 53.04% YoY), while the FY2026 annual figure was -$969.6 million, down 54.2% from the prior year.
- Cash from Financing Activities was -$457.1 million for Q2 2026 at Exelixis, down from -$254.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $5.7 million in Q3 2024 to a low of -$457.1 million in Q2 2026.
- Historically, Cash from Financing Activities has averaged -$153.0 million across 5 years, with a median of -$184.0 million in 2024.
- Biggest YoY gain for Cash from Financing Activities was 2137.07% in 2023; the steepest drop was 10678.85% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at -$2.0 million in 2022, then tumbled by 10193.21% to -$206.2 million in 2023, then surged by 102.76% to $5.7 million in 2024, then slumped by 1923.38% to -$103.9 million in 2025, then slumped by 340.12% to -$457.1 million in 2026.
- The last three Cash from Financing Activities figures came in at -$457.1 million (Q2 2026), -$254.6 million (Q1 2026), and -$103.9 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | -457.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -457.11 Mn |
| Apr 3, 2026 | -457.11 Mn |
| Jan 2, 2026 | -254.57 Mn |
| Jan 2, 2026 | -254.57 Mn |
| Oct 3, 2025 | -103.86 Mn |
| Oct 3, 2025 | -103.86 Mn |
| Jul 4, 2025 | -316.34 Mn |
| Jul 4, 2025 | -316.34 Mn |
| Apr 4, 2025 | -294.82 Mn |
| Apr 4, 2025 | -294.82 Mn |
| Jan 3, 2025 | -188.03 Mn |
| Jan 3, 2025 | -188.03 Mn |
| Sep 27, 2024 | 5.70 Mn |
| Sep 27, 2024 | 5.70 Mn |
| Jun 28, 2024 | -262.42 Mn |
| Jun 28, 2024 | -262.42 Mn |
| Mar 29, 2024 | -184.05 Mn |
| Mar 29, 2024 | -184.05 Mn |
| Dec 29, 2023 | -206.17 Mn |
| Dec 29, 2023 | -206.17 Mn |